A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Recruiting
The purpose of ARTEMIDE-Lung04 is to assess the efficacy and safety of rilvegostomig compared with pembrolizumab monotherapy as 1L treatment in participants with mNSCLC and whose tumors express PD-L1.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2025
Locations: Research Site, Bay Pines, Florida +179 locations
Conditions: Carcinoma, Non-Small Cell Lung
A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
Recruiting
This is a study evaluating the safety, pharmacokinetics, and efficacy of MK-1084 alone, and MK-1084 plus other combination therapies in participants with advanced solid tumors with identified kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2025
Locations: Moffitt Cancer Center ( Site 0261), Tampa, Florida +70 locations
Conditions: Advanced Solid Tumors
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Recruiting
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with locally advanced or metastatic solid tumors, or recurrent or progressive primary central nervous system (CNS) tumors harboring BRAF fusions, or in participants with rare BRAF V600-mutated solid tumors, melanoma, thyroid, or recurrent primary CNS tumors.
Gender:
ALL
Ages:
10 years and above
Trial Updated:
07/23/2025
Locations: UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California +59 locations
Conditions: Cancer Harboring BRAF Alterations, HGG, LGG, Solid Tumors, Melanoma BRAF V600E/K Mutated, Thyroid Cancer
Personalized Hypoglycemia Outpatient Treatment - a Feasibility Study
Recruiting
This study will offer two study interventions designed to bring on a mild low blood sugar (capillary blood glucose result 3.0 to 3.8 mmol/L), in order to study the effectiveness of each study participant's personal choice of treatment and first recheck time. The two study interventions that the participant can choose to complete (one or both interventions). Based on each participant's own experience with hypoglycemia treatment or their preferences, the participant can choose one of 4 simple ca... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2025
Locations: The Ottawa Hospital, Ottawa, Ontario
Conditions: Type 2 Diabetes (T2DM), Hypoglycemia (Diabetic)
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
Recruiting
The purpose of this study is to compare the efficacy and safety of BMS-986365 versus the investigator's choice of therapy in participants with Metastatic Castration-resistant Prostate Cancer.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/23/2025
Locations: Local Institution - 0330, Birmingham, Alabama +247 locations
Conditions: Metastatic Castration-resistant Prostate Cancer
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
Recruiting
This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) and domvanalimab (AB154) compared with durvalumab plus placebo in adults with locally advanced (Stage III), unresectable NSCLC whose disease has not progressed following definitive platinum-based cCRT.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2025
Locations: Research Site, Chandler, Arizona +257 locations
Conditions: Non-Small Cell Lung Cancer
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
Recruiting
The main purpose of this study is to determine the safety and efficacy of eltrekibart and mirikizumab in adult participants with moderately to severely active ulcerative colitis (UC).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/22/2025
Locations: AZ Gastro Care - Chandler, Chandler, Arizona +193 locations
Conditions: Ulcerative Colitis, Ulcerative Colitis Chronic
Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy
Recruiting
The purpose of this study is to evaluate how safe and how well a treatment works compared to placebo for people with nerve pain that begins in their feet and moves up the leg to just below the knee. Participation may last up to 30 weeks including screening.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: MD First Research - Chandler, Chandler, Arizona +80 locations
Conditions: Neuropathic Pain, Distal Sensory Polyneuropathy
An Ophthalmic Safety Study in Patients With Breast Cancer
Recruiting
To assess ophthalmic health in parallel cohorts of patients with breast cancer
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
07/22/2025
Locations: Research Site, La Jolla, California +74 locations
Conditions: Ophthalmic Safety in Patients With Breast Cancer
A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)
Recruiting
The primary purpose of the study is evaluate the effect of brensocatib compared with placebo.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/22/2025
Locations: USA007, Sacramento, California +62 locations
Conditions: Hidradenitis Suppurativa
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
Recruiting
Hidradenitis suppurativa (HS) is an inflammatory skin disease that causes painful lesions in the axilla (underarm), inguinal (groin) and anogenital (anal/genital) regions. This study will assess how safe and effective upadacitinib is in treating adult and adolescent participants with moderate to severe HS who have failed to respond to or are intolerant of anti-tumor necrosis factor (TNF) therapy. Adverse events and change in disease activity will be assessed. Upadacitinib is an approved drug fo... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/22/2025
Locations: Cahaba Dermatology & Skin Health Center /ID# 254876, Birmingham, Alabama +266 locations
Conditions: Hidradenitis Suppurativa
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
Recruiting
The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's disease occurring in participants receiving study drug compared to placebo. Participation could last up to 255 weeks including screening, a double-blind treatment period, and a double-blind observation period. In addition, eligible participants who receive placebo during the double-blind treatment period may choose to extend their study participat... Read More
Gender:
ALL
Ages:
Between 55 years and 80 years
Trial Updated:
07/22/2025
Locations: Parkway Medical Center, Birmingham, Alabama +278 locations
Conditions: Alzheimer's Disease